Characteristics of anal canal squamous cell carcinoma as an HPV-associated cancer in Japan.


Journal

International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 28 02 2023
accepted: 06 04 2023
medline: 23 10 2023
pubmed: 28 4 2023
entrez: 28 4 2023
Statut: ppublish

Résumé

The definition of the anal canal was revised in the TNM classification (8th edition). The Japanese Society for Cancer of the Colon and Rectum (JSCCR) conducted a retrospective multi-institutional study to clarify the characteristics of anal canal cancer (ACC) in Japan. The diagnoses of 1781 patients treated for ACC were squamous cell carcimoma (SCC; n = 428; 24.0%), adenosquamous cell carcinoma (n = 7; 0.4%), and adenocarcinoma (n = 1260; 70.7%). Anal carcinoma is associated with human papillomavirus (HPV) infection and is risk factor for anal SCC. Among 40 cases analyzed at Takano Hospital and 47 cases analyzed at National Cancer Center Hospital, 34 cases (85.0%) and 40 cases (85.1%), respectively were infected with HPV; HPV-16 was the most common genotype (79.4% and 82.5%). In the JSCCR retrospective multi-institutional study, the prognosis analysis by stage was performed for anal SCC cases (202 cases treated by CRT and 91 cases treated by surgery). The 5-year overall survival (OS) rates by stage did not differ between the two treatment groups to a statistically significant extent. Regarding the results of cancer treatment of patients who underwent HPV infection tests, although the 5-year OS rates by stage did not differ to a statistically significant extent due to the small number of cases, HPV-positive patients had better survival. While an HPV vaccine for anal canal SCC has already been approved internationally, HPV vaccination has already been implemented in Japan as a national immunization program for young women but not for men at present. An HPV vaccination for men is urgently needed.

Identifiants

pubmed: 37115427
doi: 10.1007/s10147-023-02339-5
pii: 10.1007/s10147-023-02339-5
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

990-998

Informations de copyright

© 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Références

Clark MA, Hartley A, Geh JI (2004) Cancer of the anal canal. Lancet Oncol 5:149–157
doi: 10.1016/S1470-2045(04)01410-X pubmed: 15003197
Yamada K, Saiki Y, Komori K et al (2022) Characteristics of anal canal cancer in Japan. Cancer Med 11:2735–2743
doi: 10.1002/cam4.4631 pubmed: 35274487 pmcid: 9302302
Vonsky M, Shabaeva M, Runov A et al (2019) Carcinogenesis associated with human papillomavirus infection. Mechanisms and potential for immunotherapy. Biochem Mosc 84(7):782–799
doi: 10.1134/S0006297919070095
Tilston P (1997) Anal human papillomavirus and anal cancer. J Clin Pathol 50:625–634
doi: 10.1136/jcp.50.8.625 pubmed: 9301544 pmcid: 500098
Palefsky J (2008) Human papillomavirus and anal neoplasia. Curr HIV/AIDS Rep 5:78–85
doi: 10.1007/s11904-008-0013-5 pubmed: 18510893
Brierley JD, Gospodarowicz MK, Wittekind C (2017) Anal canal and perianal skin. In: Brierley JD, Gospodarowicz MK, Wittekind C (eds) TNM classification of malignant tumours, 8th edn. Wiley Blackwell, pp 77–79
Welton ML, Steele SR, Goodman KA et al (2017) Anus. In: Amin MB (ed) AJCC Cancer Staging Manual, 8th edn. Springer, pp 275–284
doi: 10.1007/978-3-319-40618-3_21
Klas JV, Rothenberger DA, Wong WD et al (1999) Malignant tumors of the anal canal. The spectrum of disease, treatment, and outcomes. Cancer 85:1686–1693
doi: 10.1002/(SICI)1097-0142(19990415)85:8<1686::AID-CNCR7>3.0.CO;2-7 pubmed: 10223561
Johnson LG, Madeleine MM, Newcomer LM et al (2004) Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. Cancer 101:281–288
doi: 10.1002/cncr.20364 pubmed: 15241824
Joseph DA, Miller JW, Wu X et al (2008) Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 113:2892–2900
doi: 10.1002/cncr.23744 pubmed: 18980293
Brewster DH, Bhatti LA (2006) Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975–2002. Br J Cancer 95:87–90
doi: 10.1038/sj.bjc.6603175 pubmed: 16721368 pmcid: 2360500
Cancer research UK: Anal Cancer Statistic https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/anal-cancer#heading-Zero . Accessed 13 Feb 2023
Sumikoshi Y (1982) Multi-institutional registration of anal cancer in Japan. J Jpn Soc Coloproctol 35:92–97
Sameshima S, Sawada T, Nagasako K (2005) Squamous cell carcinoma of anus and carcinoma in association with anal fistula in Japan. J Jpn Soc Coloproctol 58:415–421
doi: 10.3862/jcoloproctology.58.415
Nielsen A, Munk C, Kjaer SK (2012) Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978–2008. Int J Cancer 130:1168–1173
doi: 10.1002/ijc.26115 pubmed: 21469144
Jin F, Stein AN, Conway EL et al (2011) Trends in anal cancer in Australia, 1982–2005. Vaccine 29:2322–2327
doi: 10.1016/j.vaccine.2011.01.015 pubmed: 21255682
Daling JR, Madeleine MM, Johnson LG et al (2004) Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101:270–280
doi: 10.1002/cncr.20365 pubmed: 15241823
Frisch M, Glimelius B, van den Brule AJ et al (1997) Sexually transmitted infection as a cause of anal cancer. N Engl J Med 337:1350–1358
doi: 10.1056/NEJM199711063371904 pubmed: 9358129
Jimenez W, Paszat L, Kupets R et al (2009) Presumed previous human papillomavirus related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecol Oncol 114:395–398
doi: 10.1016/j.ygyno.2009.05.006 pubmed: 19501390
Ryan DP, Compton CC, Mayer RJ (2000) Carcinoma of the anal canal. N Engl J Med 342:792–800
doi: 10.1056/NEJM200003163421107 pubmed: 10717015
Sunesen KG, Norgaard M, Thorlacius-Ussing O et al (2010) Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978–2005. Int J Cancer 127:675–684
doi: 10.1002/ijc.25080 pubmed: 19960431
Frisch M, Biggae RJ, Goedert JJ (2000) Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92:1500–1510
doi: 10.1093/jnci/92.18.1500 pubmed: 10995805
Uronis HE, Bendell JC (2007) Anal cancer: an overview. Oncologist 12:524–534
doi: 10.1634/theoncologist.12-5-524 pubmed: 17522240
Koulos J, Symmans F, Chumas J et al (1991) Human papillomavirus detection in adenocarcinoma of the anus. Mod Patho 4(1):58–61
Alemany L, Saunier M, Alvarado I et al (2015) HPV DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 136(1):98–107
doi: 10.1002/ijc.28963 pubmed: 24817381
Ito T, Takayanagi D, Sekine S et al (2013) Comparison of clinicopathological and genomic profiles in anal squamous cell carcinoma between Japanese and Caucacian cohorts. Sci Rep 13(1):3587
doi: 10.1038/s41598-023-30624-w
Boman BM, Moertel CG, O’Connell MJ et al (1984) Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer 54:114–125
doi: 10.1002/1097-0142(19840701)54:1<114::AID-CNCR2820540124>3.0.CO;2-P pubmed: 6326995
Nigro ND (1984) An evaluation of combined therapy for squamous cell cancer of the anal canal. Dis Colon Rectum 27:763–766
doi: 10.1007/BF02553933 pubmed: 6499614
National Comprehensive Cancer Network (2023) Anal carcinoma. Version 1. https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf . Accessed 23 Jan 2023
Rodel F, Wieland U, Fraunholz I et al (2015) Human papillomavirus DNA load and p16
doi: 10.1002/ijc.28979 pubmed: 24839133
Serup-Hansen E, Linnemann D, Skovrider-Ruminski W et al (2014) Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American joint committee on cancer stage I to III carcinoma of the anal canal. J Clin Oncol 32:1812–1817
doi: 10.1200/JCO.2013.52.3464 pubmed: 24821878
Urbute A, Rasmussen CL, Belmonte F et al (2020) Prognostic significance of HPV DNA and p16
doi: 10.1158/1055-9965.EPI-19-1259 pubmed: 32051192
Parwaiz I, MacCabe TA, Thomas MG et al (2019) A systematic review and meta-analysis of prognosis biomarkers in anal squamous cell carcinoma treated with primary chemoradiotherapy. Clin Oncol 31(12):e1–e13
doi: 10.1016/j.clon.2019.06.013
https://www.cdc.gov/hpv/hcp/protecting-patients.html . Accessed 15 Feb 2023
https://www.cdc.gov/hpv/hcp/schedules-recommendations.html . Accessed 15 Feb 2023
https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-vaccine.html . Accessed 15 Feb 2023
https://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-human-papillomavirus-vaccine-immunization-schedule.html . Accessed 15 Feb 2023
Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction. European Centre for Disease Prevention and Control (2020)
Hall MT, Simms KT, Lew JB et al (2019) The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health 4:e19–e27
doi: 10.1016/S2468-2667(18)30183-X pubmed: 30291040

Auteurs

Kazutaka Yamada (K)

Department of Surgery, Coloproctology Center Takano Hospital, 3-2-55 Oe, Chuo-ku, Kumamoto, 862-0971, Japan. k-yamada@magma.jp.

Kouya Shiraishi (K)

Division of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Atsuo Takashima (A)

Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Daisuke Takayanagi (D)

Division of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Yasumitsu Saiki (Y)

Department of Surgery, Coloproctology Center Takano Hospital, 3-2-55 Oe, Chuo-ku, Kumamoto, 862-0971, Japan.

Shota Takano (S)

Department of Surgery, Coloproctology Center Takano Hospital, 3-2-55 Oe, Chuo-ku, Kumamoto, 862-0971, Japan.

Masafumi Tanaka (M)

Department of Surgery, Coloproctology Center Takano Hospital, 3-2-55 Oe, Chuo-ku, Kumamoto, 862-0971, Japan.

Mitsuko Fukunaga (M)

Department of Surgery, Coloproctology Center Takano Hospital, 3-2-55 Oe, Chuo-ku, Kumamoto, 862-0971, Japan.

Kosuke Sugimoto (K)

Division of Medical Information Research, Coloproctology Center Takano Hospital, 3-2-55 Oe, Chuo-ku, Kumamoto, 862-0971, Japan.

Yuki Iwasaki (Y)

Division of Medical Information Research, Coloproctology Center Takano Hospital, 3-2-55 Oe, Chuo-ku, Kumamoto, 862-0971, Japan.

Yasushi Nakamura (Y)

Department of Surgery, Coloproctology Center Takano Hospital, 3-2-55 Oe, Chuo-ku, Kumamoto, 862-0971, Japan.

Daisaku Kuwahara (D)

Department of Surgery, Coloproctology Center Takano Hospital, 3-2-55 Oe, Chuo-ku, Kumamoto, 862-0971, Japan.

Yoriyuki Tsuji (Y)

Department of Surgery, Coloproctology Center Takano Hospital, 3-2-55 Oe, Chuo-ku, Kumamoto, 862-0971, Japan.

Masahiro Takano (M)

Department of Surgery, Coloproctology Center Takano Hospital, 3-2-55 Oe, Chuo-ku, Kumamoto, 862-0971, Japan.

Kenichi Sugihara (K)

Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.

Yoichi Ajioka (Y)

Division of Molecular and Diagnostic Pathology, Niigata University Graduate School of Medical and Dental Sciences, 757 Ichibancho, Asahimachi-dori, Chuo Ward, Niigata, 951-8510, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH